#USA #Salt Lake City #Rebel Medicine #Alevatrix #pain therapy

Rebel Medicine Secures Series A Financing

Rebel Medicine Inc, a pioneering biotechnology firm based in Salt Lake City, has announced a significant milestone in its journey toward innovative pain management solutions. They recently closed a Series A financing round, garnering $6 million to accelerate the clinical development of their leading non-opioid pain therapeutic, Alevatrix™. This funding round, led by Crocker Ventures, included notable contributions from Central Texas Angel Network (CTAN), Prosperity Solutions Capital, and various other life-science investors.

The timing of this financing coincides with the official opening of their Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), allowing Rebel Medicine to enter the next phase of their clinical trials. The primary goal of this funding is to facilitate a first-in-human Phase 2 clinical trial involving randomized, dose-escalation testing on bunionectomy patients. This trial aims to evaluate the safety and efficacy of Alevatrix™, marking a crucial step in its development.

According to Brett Davis, PhD, the Co-Founder and CEO of Rebel Medicine, this funding is not just a financial achievement; it reinforces the company's vision and validates the potential of their technologies. “This is a transformative moment for Rebel Medicine,” stated Davis, emphasizing that the successful fundraising and IND clearance will significantly accelerate the progression of Alevatrix™ through clinical development. The ultimate aim of the company is to provide effective, opioid-sparing alternatives for pain management, addressing a critical need in post-operative care.

About Alevatrix™

Alevatrix™ is an innovative formulation of bupivacaine, known for its well-established role as a local anesthetic. This drug is uniquely developed within a proprietary injectable matrix designed by Rebel Medicine. This formulation aims to deliver medication directly at the site of administration for an extended period—up to 72 hours—potentially reducing, if not eliminating, the need for traditional opioids following surgical procedures. Preclinical studies have suggested that Alevatrix™ achieves prolonged analgesic effects without the adverse effects commonly associated with opioid medications, showcasing a favorable safety profile.

The Future of Rebel Medicine

Rebel Medicine Inc is dedicated to revolutionizing the landscape of pain management by leveraging their proprietary delivery technologies. Their approach not only aims to enhance the efficacy of existing pharmaceuticals but also seeks to provide innovative solutions to urgent clinical needs, reducing development times and associated risks.

The company, headquartered in Salt Lake City, is actively developing additional pipeline programs that capitalize on their unique delivery systems, promising to extend the release of injectable medications from days to several months. As they forge ahead, the commitment of Rebel Medicine to push boundaries in healthcare continues to evolve, as does its potential to change lives by minimizing reliance on opioids in pain management.

With updates and future announcements, those interested can connect with Rebel Medicine on LinkedIn, staying informed on their progress and breakthroughs in the field of biotechnology.